Over the past decade the use of magnetic resonance imaging (MRI) has witnessed a sharp increase[1](#jmri24971-bib-0001){ref-type="ref"}, [2](#jmri24971-bib-0002){ref-type="ref"}, [3](#jmri24971-bib-0003){ref-type="ref"} as the modality of choice for diagnosing a spectrum of conditions.[4](#jmri24971-bib-0004){ref-type="ref"} For joint pain and lower back pain, MRI is cited as an appropriate diagnostic method by the American College of Radiology.[5](#jmri24971-bib-0005){ref-type="ref"} For stroke, an MRI method known as diffusion‐weighted imaging (DWI), has emerged as a sensitive and specific technique.[6](#jmri24971-bib-0006){ref-type="ref"}, [7](#jmri24971-bib-0007){ref-type="ref"}, [8](#jmri24971-bib-0008){ref-type="ref"} In these conditions and others, such as cardiomyopathy,[9](#jmri24971-bib-0009){ref-type="ref"}, [10](#jmri24971-bib-0010){ref-type="ref"}, [11](#jmri24971-bib-0011){ref-type="ref"}, [12](#jmri24971-bib-0012){ref-type="ref"} MRI has emerged as a preferred imaging modality because it provides excellent spatial resolution without exposing patients to ionizing radiation, iodinated contrast agents, and risks of invasive procedures.[13](#jmri24971-bib-0013){ref-type="ref"}

The use of MRI technology is expected to grow in tandem with the expanding number of cardiovascular patients,[13](#jmri24971-bib-0013){ref-type="ref"} and the increasing number of cardiovascular indications for MRI.[5](#jmri24971-bib-0005){ref-type="ref"}, [11](#jmri24971-bib-0011){ref-type="ref"} At the same time, there is a corresponding rise in the volume of patients receiving implantable cardioverter defibrillators (ICDs),[13](#jmri24971-bib-0013){ref-type="ref"}, [14](#jmri24971-bib-0014){ref-type="ref"} with an estimated 2.9 million implanted between 1993--2009 in the U.S..[15](#jmri24971-bib-0015){ref-type="ref"} In 2013, the National ICD Registry published a report on the latest entries into its database, including the number of ICDs implanted in the U.S. for quarters 2--4 in 2010 and all of 2011. According to the report, there were ∼263,000 ICD procedures over the time period, translating to 12,500 per month.[16](#jmri24971-bib-0016){ref-type="ref"}

The importance of MRI in the growing population of ICD recipients is underscored by the ongoing concerns regarding its safety. MRI scanners utilize static and gradient magnetic fields and radiofrequency energy[11](#jmri24971-bib-0011){ref-type="ref"}, [12](#jmri24971-bib-0012){ref-type="ref"} that can disable or reset ICD electronics, result in inappropriate therapies or inhibit needed therapy, exert force upon the generator, or heat ICD components.[14](#jmri24971-bib-0014){ref-type="ref"} The U.S. Food and Drug Administration (FDA), in a statement updated in 2014, advises caution and summarizes possible hazards of ICD interaction with MRI.[17](#jmri24971-bib-0017){ref-type="ref"} Also in 2014, the Canadian Heart Rhythm Society and Canadian Association of Radiologists published a Consensus Statement summarizing potential risks in scanning patients with non‐MR conditional devices. The Statement notes that scanning of these patients is not endorsed by Health Canada, and should be avoided unless there is a compelling medical need.[18](#jmri24971-bib-0018){ref-type="ref"}

Studies have shown that MRI examination can safely be performed on modern ICD recipients if safety protocols are followed.[19](#jmri24971-bib-0019){ref-type="ref"}, [20](#jmri24971-bib-0020){ref-type="ref"} Yet, despite the growing evidence, the safety concerns continue, and the impact of ICD implantation on diagnostic imaging utilization has not been clearly defined.

The purpose of this study was to examine imaging utilization in a matched cohort of patients with and without ICDs and to project MRI utilization over a 10‐year period.

Materials and Methods {#jmri24971-sec-0006}
=====================

The methodology compares utilization of imaging in the ICD and nonimplant cohorts to illustrate the gap in volume of imaging linked to restrictions in its use in patients with ICDs. The study also compares utilization in subsets of the cohorts, including stroke, back pain, and joint pain. Four calendar years of MRI utilization in the nonimplant cohort was utilized to forecast the potential utilization for MRI over a 10‐year time horizon.

Data Source {#jmri24971-sec-0007}
-----------

This study used data from the Truven Health MarketScan Commercial Claims and Medicare Supplemental Research Databases, which contain Health Insurance Portability and Accountability Act (HIPAA)‐compliant, individual‐level, deidentified, healthcare claims information from employers, health plans, hospitals, Medicare, and Medicaid programs. Research using MarketScan data has been widely published in peer‐reviewed journals, including the field of imaging.[21](#jmri24971-bib-0021){ref-type="ref"}, [22](#jmri24971-bib-0022){ref-type="ref"} A protocol describing the study objectives, criteria for patient selection, data elements of interest, and statistical methods was submitted to the New England Institutional Review Board (NEIRB) and deemed exempt from review (NEIRB \#13--343).

Patient Selection and Identification {#jmri24971-sec-0008}
------------------------------------

Patient‐level data were extracted from the Truven Health MarketScan Research Databases for the years 2009--2012. Two cohorts were defined: 1) patients having a record of an ICD implant: \"ICD implant cohort\"; 2) patients without a record of a cardiac device or other implantable device that is contraindicated for MRI: \"nonimplant cohort.\" The following inclusion/exclusion criteria were then applied to each cohort: ICD Implant Cohort: Patients with continuous health plan enrollment in the calendar year 2012 who had a record of an ICD implant for that entire calendar year were identified (Appendix [Implant Code Combinations](#jmri24971-app-0001){ref-type="app"}, implant codes). (Note: patients had to have a record of an implant prior to the start of the calendar year 2012 and could not have a record of an explant \[Appendix [Explant Codes](#jmri24971-app-0002){ref-type="app"}\] anytime during that year).Nonimplant Cohort: Patients with continuous health plan enrollment in 2009--2012 without a record of any cardiac or contraindicated MRI implant or related monitoring codes (Appendix [Implant Code Combinations](#jmri24971-app-0001){ref-type="app"}--[Interrogation and Evaluation Codes](#jmri24971-app-0003){ref-type="app"}) during the entire 4‐year time period were identified.

Variables of Interest {#jmri24971-sec-0009}
---------------------

The main outcome measure analyzed was yearly (2012) diagnostic imaging utilization which was organized into the following six categories: 1) computed tomography (CT) and computed tomography angiography (CTA);[2](#jmri24971-bib-0002){ref-type="ref"} MRI and magnetic resonance angiogram (MRA); 3) ultrasound, echo, Doppler, and duplex; 4) X‐ray and fluoroscopy; 5) nuclear; and 6) other. Diagnostic imaging utilization was then measured two different ways: i) by the number of procedures overall and across each category, and ii) by the number of actual patients having a procedure within each category.

The main independent variable for this analysis was whether a patient was in the ICD cohort or the nonimplant cohort. Explanatory variables included patient demographics (age, gender, and type of plan) and patient comorbidities (diabetes, hypertension, chronic pulmonary obstruction disease \[COPD\], etc.). See Appendix [Comorbid Condition Codes and Anticoagulation Specification](#jmri24971-app-0004){ref-type="app"} for a complete listing of all comorbidities and their corresponding diagnostic codes.

Three additional variables were created to further subdivide the population. This included patients with a diagnosis code on record for the year 2012 for the following diseases: acute stroke, back pain, and joint pain. For the calendar year 2012, patients with ICD‐9 diagnosis codes for stroke or transient ischemic attack (TIA) had their diagnostic imaging utilization summarized within ±3 days of the stroke/TIA event. Patients with ICD‐9 diagnosis codes for back pain or joint pain had their diagnostic imagining utilization summarized within 3 days before and 30 days after their first diagnosis on record.

Statistical Analysis {#jmri24971-sec-0010}
--------------------

All data were imported and maintained in SAS data files. Tabulation of summary statistics, graphical presentations, and data analyses were performed using SAS v. 9.2. (SAS Institute, Cary, NC).

Once all variables were created, patients in the ICD implant cohort were matched 1:1 using a combination of direct (age, gender, type of plan) and propensity score matching (comorbid conditions) to patients in the nonimplant cohort. A full list of comorbid conditions used for the propensity score are listed in Appendix [Comorbid Condition Codes and Anticoagulation Specification](#jmri24971-app-0004){ref-type="app"}. Propensity score matching, or conditional probability of assignment to a particular treatment given a set of observed characteristics, has been shown to balance the number of confounders among matched cohorts. The propensity score was calculated from a logistic regression model as the probability that a patient was assigned to a particular treatment given the patient\'s comorbid conditions. From this model, individual propensity scores were calculated for each patient as a measure of the likelihood that the patient would have been in the ICD cohort versus the nonimplant cohort. An SAS macro from the Mayo Clinic (gmatch) was used to create a greedy match based on the propensity score.[23](#jmri24971-bib-0023){ref-type="ref"}, [24](#jmri24971-bib-0024){ref-type="ref"} This method utilizes random selection of treatment subjects and chooses the nearest matching nonimplant subject. Once matched, the pairs will not be broken, even for a more optimal match.

Propensity Score Logit Model: {#jmri24971-sec-0011}
-----------------------------

$$p_{i} = \frac{e\left( {\beta_{0} + \beta_{1}X_{1i} + \cdots + \beta_{p}X_{pi}} \right)}{1 + e\left( {\beta_{0} + \beta_{1}X_{1i} + \cdots + \beta_{p}X_{pi}} \right)}$$Where *p~i~* is the likelihood of ICD implant for the *i^th^* patient (*i* = 1,...,n) and *X~1i~...X~ip~* are covariate characteristics for the *i^th^* patient.

Diagnostic imaging utilization was compared across the matched cohorts, in total, by imaging category (MRI, CT scan, X‐ray, etc.), and for MRI by body area for the calendar year 2012. The same comparison was carried out for the following three subpopulations of interest: acute stroke/TIA, back pain, and joint pain.

Predicting the Probability of MRI Utilization: 10‐Year Time Horizon

In an effort to further understand MRI utilization, the nonimplant matched cohort was used to measure the percent of patients with ICDs who needed an MRI over the 4‐year period.(2009 ‐2012) This survival data were then fitted with exponential functions to forecast a range of best fit scenarios, as measured by the coefficient of determination, out to 10 years.

Results {#jmri24971-sec-0012}
=======

A total of 97,150,333 patients from the Truven Health MarketScan Research Databases were identified as meeting the initial inclusion criteria. For the 1) ICD Implant Cohort, a total of 12,615 patients had continuous health plan enrollment in the calendar year 2012 and a record of an ICD implant for that entire calendar year. For the 2) Nonimplant Cohort, a total of 13,112,933 patients had continuous health plan enrollment in 2009--2012 without a record of any cardiac or contraindicated MRI implant or related monitoring codes during the entire 4‐year time period. After 1:1 matching, the final sample was a total of 18,770 with 9,385 patients in each cohort. See Fig. [1](#jmri24971-fig-0001){ref-type="fig"} for the complete attrition diagram.

![Patient attrition diagram. ICD: implantable cardioverter defibrillator.](JMRI-43-115-g001){#jmri24971-fig-0001}

Patient demographics and comorbid conditions in the matched cohorts are shown in Tables [1](#jmri24971-tbl-0001){ref-type="table-wrap"} and [2](#jmri24971-tbl-0002){ref-type="table-wrap"}. Since direct matching was used for age, gender, and type of plan, distributions were virtually equal across cohorts. Over 70% in each cohort were 60 years of age or older and ∼78% male. Medicare and commercial insurance were distributed fairly equally, with ∼53% being Medicare and 47% commercial. The highest concentration of patients by region occurred in the north central (30%) and south (34%). All standardized differences for demographics and comorbid conditions were \<0.01, except for region.

###### 

Patient Demographics After Matching

                                           Total    Cohort                                   
  ---------------------------------------- -------- -------- ------- ------- ------- ------- --------
  Total *N*                                18,770   100.0    9,385   100.0   9,385   100.0   
  Age in January 2012                                                                        
  \<18                                     128      0.7      65      0.7     63      0.7     0.0066
  18--29                                   188      1.0      94      1.0     94      1.0     
  30--39                                   323      1.7      165     1.8     158     1.7     
  40--49                                   1,247    6.6      636     6.8     611     6.5     
  50--59                                   3,667    19.5     1,866   19.9    1,801   19.2    
  60--69                                   5,512    29.4     2,750   29.3    2,762   29.4    
  70--79                                   4,787    25.5     2,362   25.2    2,425   25.8    
  80+                                      2,918    15.6     1,447   15.4    1,471   15.7    
  Gender                                                                                     
  Male                                     14,654   78.1     7,327   78.1    7,327   78.1    0.0000
  Female                                   4,116    21.9     2,058   21.9    2,058   21.9    
  Commercial or Medicare in January 2012                                                     
  Commercial                               8,797    46.9     4,365   46.5    4,432   47.2    0.0143
  Medicare                                 9,973    53.1     5,020   53.5    4,953   52.8    
  Insurance plan in January 2012                                                             
  Missing/unknown                          538      2.9      381     4.1     157     1.7     0.0836
  Comprehensive                            5,574    29.7     2,787   29.7    2,787   29.7    
  EPO                                      196      1.0      108     1.2     88      0.9     
  HMO                                      2,185    11.6     966     10.3    1,219   13.0    
  POS                                      1,084    5.8      522     5.6     562     6.0     
  PPO                                      8,568    45.7     4,301   45.8    4,267   45.5    
  POS with Capitation                      24       0.1      12      0.1     12      0.1     
  CDHP                                     437      2.3      218     2.3     219     2.3     
  HDHP                                     164      0.9      90      1.0     74      0.8     
  Region in January 2012                                                                     
  Northeast region                         3,271    17.4     1,636   17.4    1,635   17.4    0.1849
  North central region                     5,647    30.1     2,883   30.7    2,764   29.5    
  South region                             6,507    34.7     3,330   35.5    3,177   33.9    
  West region                              3,176    16.9     1,386   14.8    1,790   19.1    
  Unknown region                           169      0.9      150     1.6     19      0.2     

CDHP: Consumer Driven Health Plans; EPO: Exclusive Provider Organization; HDHP: High Deductible Health Plan; HMO: Health Maintenance Organization; ICD: implantable cardioverter defibrillator; POS: Point Of Service; PPO: Preferred Provider Organization.

###### 

Comorbid Conditions After Matching

                                   Total    Cohort                                   
  -------------------------------- -------- -------- ------- ------- ------- ------- ---------
  All patients                     18,770   100.0    9,385   100.0   9,385   100.0   
  Rheumatoid arthritis             262      1.4      136     1.5     126     1.3     0.0091
  Psoriatic arthritis              41       0.2      22      0.2     19      0.2     0.0068
  Ankylosing spondylitis           15       0.1      5       0.1     10      0.1     0.0189
  Skin cancer                      964      5.1      529     5.6     435     4.6     0.0454
  Colon cancer                     105      0.6      63      0.7     42      0.5     0.0300
  Lung, bronchus, or trachea       150      0.8      82      0.9     68      0.7     0.0168
  GERD                             1,623    8.7      814     8.7     809     8.6     0.0019
  Gastritis                        618      3.3      312     3.3     306     3.3     0.0036
  Gastric ulcer                    81       0.4      51      0.5     30      0.3     0.0341
  Crohn\'s disease                 79       0.4      37      0.4     42      0.5     0.0082
  Ulcerative colitis               68       0.4      37      0.4     31      0.3     0.0106
  Diverticulitis                   158      0.8      79      0.8     79      0.8     0.0000
  Kidney stones                    451      2.4      240     2.6     211     2.3     0.0202
  Cystitis                         229      1.2      126     1.3     103     1.1     0.0223
  Depressive disorders             1,581    8.4      750     8.0     831     8.9     0.0311
  Neurotic disorders               1,124    6.0      500     5.3     624     6.7     0.0557
  Heart failure                    7,986    42.6     4,109   43.8    3,877   41.3    0.0500
  MI (any)                         2,570    13.7     1,347   14.4    1,223   13.0    0.0384
  Angina                           1,286    6.9      654     7.0     632     6.7     0.0093
  Other coronary artery Disease    11,545   61.5     5,794   61.7    5,751   61.3    0.0094
  Stroke                           547      2.9      309     3.3     238     2.5     0.0450
  TIA                              430      2.3      226     2.4     204     2.2     0.0157
  Cardiac dysrhythmias             11,687   62.3     5,793   61.7    5,894   62.8    0.0222
  Sleep apnea                      2,417    12.9     1,152   12.3    1,265   13.5    0.0360
  Hypertension                     12,373   65.9     6,208   66.2    6,165   65.7    0.0097
  Irritable bowel disease          152      0.8      58      0.6     94      1.0     0.0428
  Lumbar disk disease              969      5.2      465     5.0     504     5.4     0.0188
  Osteoporosis                     371      2.0      192     2.1     179     1.9     0.0100
  Osteoarthritis                   3,206    17.1     1,639   17.5    1,567   16.7    0.0204
  Parkinson\'s disease             137      0.7      79      0.8     58      0.6     0.0263
  Multiple sclerosis               51       0.3      19      0.2     32      0.3     0.0266
  Migraine                         181      1.0      69      0.7     112     1.2     0.0469
  Obstructive chronic bronchitis   784      4.2      457     4.9     327     3.5     0.0693
  Emphysema                        355      1.9      199     2.1     156     1.7     0.0336
  Chronic obstructive asthma       201      1.1      114     1.2     87      0.9     0.0280
  Bronchiectasis                   64       0.3      42      0.5     22      0.2     0.0366
  Extrinsic allergic alveolitis    6        0.0      4       0.0     2       0.0     0.0119
  Chronic airway obstruction NEC   2,268    12.1     1,262   13.5    1,006   10.7    0.0838
  Eczema (dermatitis)              580      3.1      291     3.1     289     3.1     0.0012
  Sebaceous gland diseases         546      2.9      284     3.0     262     2.8     0.0139
  Diabetes                         6,410    34.2     3,245   34.6    3,165   33.7    0.0180
  Hyperlipidemia                   10,667   56.8     5,276   56.2    5,391   57.4    0.0247
  Hypothyroidism                   2,079    11.1     991     10.6    1,088   11.6    0.0329
  Anticoagulants usage             4,170    22.2     2,126   22.7    2,044   21.8    0.0210
  Atrial fibrillation              5,996    31.9     2,760   29.4    3,236   34.5    −0.1089
  Hypertrophic cardiomypathy       382      2.0      357     3.8     25      0.3     0.2525
  Sarcoidosis                      87       0.5      72      0.8     15      0.2     0.0895

GERD: gastroesophageal reflux disease; MI: myocardial infarction; NEC: not elsewhere classified; TIA: transient ischemic attack.

After matching, ICD patients had significantly less imaging per patient compared to the nonimplant cohort (4.3 6.10 SD vs. 5.6 7.87 SD, *P* \< 0.0001). ICD patients had significantly less MRI (0.23 0.70 SD vs. 0.00 0.08 SD, *P* \< 0.0001) than the nonimplant cohort.

When evaluating the breakdown of procedures by imaging modality, there was a lower utilization of all imaging among ICD patients, with the most marked differences in MRI/MRA (2,121 nonimplant vs. 37 ICD), X‐ray and fluoroscopy (25,956 nonimplant vs. 19,577 ICD), and ultrasound (16,543 nonimplant vs. 13,692 ICD) (Fig. [2](#jmri24971-fig-0002){ref-type="fig"}A). These differences were similar in the patient‐level analysis (Fig. [2](#jmri24971-fig-0002){ref-type="fig"}B). Among those patients of each 9385 cohort, who had an MRI, the most frequently occurring MRI was of the brain (29% nonimplant vs. 30% ICD). Table [3](#jmri24971-tbl-0003){ref-type="table-wrap"} shows the number and percent of MRIs for each cohort by body area.

![**A**: Total number of procedures for each cohort by radiology category. **B:** Number of patients for each cohort by radiology category. ICD: implantable cardioverter defibrillator; CT: computed tomography; CTA: computed tomography angiography; MRI: magnetic resonance imaging; MRA: magnetic resonance angiogram.](JMRI-43-115-g002){#jmri24971-fig-0002}

###### 

MRI/MRA Scans by Body Area

  Location                   ICD   Nonimplant         
  -------------------------- ----- ------------ ----- -----
                             *N*   \%           N     \%
  Abdomen                    2     5%           112   5%
  Brain                      11    30%          607   29%
  Cardiac, breast, & chest   1     3%           91    4%
  Head                       0     0%           132   6%
  Lower extremities          6     16%          274   13%
  Neck                       0     0%           87    4%
  Other                      0     0%           37    2%
  Pelvis                     0     0%           58    3%
  Spine ‐ chest              2     5%           77    4%
  Spine ‐ lumbar             9     24%          326   15%
  Spine ‐ neck               2     5%           187   9%
  Upper extremities          4     11%          135   6%

Includes two instances of the same subcategory of MRI on the same day, causing that MRI to only be counted once previously.

MRA: magnetic resonance angiogram; MRI: magnetic resonance imaging.

Table [4](#jmri24971-tbl-0004){ref-type="table-wrap"} depicts the overall differences in imaging utilization between ICD and nonimplant patients across the three subpopulations: stroke/TIA, back pain, and joint pain. Among patients with records of stroke/TIA (ICD 5%, nonimplant 4%) and accompanying diagnostic imaging, 44% of nonimplant patients underwent MRI vs. 1% of ICD patients (*P* \< 0.0001) (Fig. [3](#jmri24971-fig-0003){ref-type="fig"}A) and nonimplant patients had more imaging tests overall (4.1 2.47 SD vs. 3.2 2.16 SD, *P* \< 0.0001). Among patients with records of back pain and accompanying diagnostic imaging, 22% of nonimplant patients underwent MRI vs. 0.7% of ICD patients (*P* \< 0.0001) (Fig. [3](#jmri24971-fig-0003){ref-type="fig"}B), and nonimplant patients had more imaging tests overall (2.5 2.80 SD vs. 2.0 2.04 SD, *P* = 0.0003). By comparison, patients with records of back pain and ICDs underwent a statistically significantly larger volume of CT and CTA (32%) as compared to the nonimplant cohort (21%) (*P* = 0.0011). Among patients with records of joint pain and accompanying diagnostic imaging, 17% of nonimplant patients underwent MRI vs. 0.1% of ICD patients (*P* \< 0.0001) (Fig. [3](#jmri24971-fig-0003){ref-type="fig"}C), and nonimplant patients had more imaging tests overall (2.5 2.77 SD vs. 2.1 1.89 SD, *P* \< 0.0001). Similar to the back pain subgroup, patients with joint pain records and ICDs underwent CT and CTA more often (19%) than patients with joint pain in the nonimplant cohort (16%). The difference, however, was not statistically significant.

###### 

Subgroup Radiology

  Subpopulation   Category                         ICD           Nonimplant                         
  --------------- -------------------------------- ------------- ------------ ------------- ------- ---------
  Stroke/TIA      Total patients (% of total)      442 (5%)                   379 (4%)              
                  Total with imaging               304           962          285           1,160   
                  CT & CTA                         228           339          204           294     0.8916
                  MRI & MRA                        3             3            125           184     \<.0001
                  Nuclear                          11            11           5             5       0.2274
                  Other                            0             0            1             1       0.2804
                  Ultrasound/Echo/Doppler/Duplex   209           334          206           349     0.0165
                  X‐Ray & Fluoroscopy              184           275          194           327     0.0003
  Back pain       Total patients (% of total)      1,552 (17%)                1,681 (18%)           
                  Total with imaging               869           1,776        930           2,284   
                  CT & CTA                         274           349          198           262     0.0011
                  MRI & MRA                        6             6            203           235     \<.0001
                  Nuclear                          49            51           72            76      0.0850
                  Other                            0             0            1             1       0.3175
                  Ultrasound/echo/Doppler/duplex   235           324          270           422     0.0626
                  X‐ray & fluoroscopy              694           1,046        744           1,288   0.0501
  Joint pain      Total patients (% of total)      2,073 (22%)                2,355 (25%)           
                  Total with imaging               1,456         3,005        1,668         4,142   
                  CT & CTA                         273           347          270           347     0.1649
                  MRI & MRA                        2             2            277           315     \<.0001
                  Nuclear                          102           105          109           117     0.8886
                  Other                            1             1            2             2       0.6339
                  Ultrasound/echo/Doppler/duplex   403           568          500           764     0.0193
                  X‐ray & fluoroscopy              1,280         1,982        1,472         2,597   0.0009

CT: computed tomography; CTA: computed tomography angiography; MRI: magnetic resonance imaging; MRA: magnetic resonance angiogram.

![**A**: Percentage of patients with stroke/TIA event by radiology type. **B:** Percentage of patients with back pain by radiology type. **C:** Percentage of patients with joint pain by radiology type. ICD: implantable cardioverter defibrillator; CT: computed tomography; CTA: computed tomography angiography; MRI: magnetic resonance imaging; MRA: magnetic resonance angiogram.](JMRI-43-115-g003){#jmri24971-fig-0003}

The proportion of nonimplant patients who received an MRI or MRA at 1, 2, 3, and 4 years and projected to 10 years are shown in Fig. [4](#jmri24971-fig-0004){ref-type="fig"}. These ICD‐indicated patients had a projected MRI or MRA utilization of between 53% and 64% within 10 years.

![MRI/MRA use by ICD‐indicated patients and projected utilization to 10 years. The black line represents the proportion of ICD‐indicated patients who received an MRI or MRA at 1, 2, 3, and 4 years. The lines extending after year 4 show two projections, which are high and low estimates of utilization. MRI: magnetic resonance imaging; MRA: magnetic resonance angiogram; ICD: implantable cardioverter defibrillator.](JMRI-43-115-g004){#jmri24971-fig-0004}

Discussion {#jmri24971-sec-0013}
==========

These findings of minimal utilization of MRIs among ICD patients suggest continued reluctance to perform MRIs in those patients and an unmet need for MRIs, yet this practice conflicts with the current trend toward greater use of complex imaging. The volume of patients with ICDs is growing, and for much of the last decade Medicare Part B spending on complex scanning methods, including MRI, rose an average 17% per year. This indicates a spending pattern that is nearly twice that of spending on ultrasound, radiography, and other standard imaging procedures.[2](#jmri24971-bib-0002){ref-type="ref"} MRI volume flattened somewhat mid‐decade,[25](#jmri24971-bib-0025){ref-type="ref"} following implementation of the Deficit Reduction Act in 2007,[26](#jmri24971-bib-0026){ref-type="ref"} but the overall trajectory is upward.[1](#jmri24971-bib-0001){ref-type="ref"} According to a recent report from the Medicare Payment Advisory Committee, the number of brain MRIs per 1000 Medicare beneficiaries rose to 75 in 2012, up from 44 in 2000. Likewise, the number of \"other\" MRIs jumped to 129 per 1000 in 2012, versus 58 in 2000.

Further evidence of the growing role of MRIs comes from Appropriateness Criteria from the American College of Radiology, which are evidenced‐based guidelines designed to help imaging decision‐making. The Appropriateness Criteria consistently rank MRI as an appropriate diagnostic tool for a wide range of musculoskeletal, neurologic, cardiac, and other conditions.[5](#jmri24971-bib-0005){ref-type="ref"} In the case of low back pain, for example, MRI is highly rated as a preferred modality, ranking an \"8\" out of a possible \"9\" for patients with a suspicion of cancer, infection, or immunosuppression, or in patients with low‐velocity trauma, osteoporosis, focal and/or progressive deficit, prolonged symptom duration, or greater than 70 years of age. By comparison, for this same indication, use of a CT scan is rated \"6,\" which suggests this approach \"may be appropriate.\" Similarly, for pain in the hip joint, an MRI without contrast is rated a \"9\" for patients who are radiograph negative, equivocal, or nondiagnostic, and have suspected osseous or surrounding soft‐tissue abnormality, excluding osteoid osteoma. A CT scan for this indication is rated \"2,\" which translates as \"usually not appropriate.\"

Given the evidenced‐based importance of MRI as a valued diagnostic tool, its minimal use in ICD patients is a concern. Our study revealed this same pattern of sharply different MRI/MRA utilization among the three matched subpopulations of interest: acute stroke/TIA, back pain, and joint pain.

At the time of this analysis, MR‐conditional ICDs were not available in the U.S., but our finding of an unmet need for imaging in patients with ICDs is similar to results from a European study where conditional ICDs have been available for a few years. A study of 51 European Heart Rhythm Association centers by Marinskis et al[27](#jmri24971-bib-0027){ref-type="ref"} focused on MRIs in patients with ICDs, and 65.8% reported never performing MRI on non‐MR‐conditional ICD recipients.

Our results indicate that despite the growing literature regarding the safety of MRI in the setting of implanted legacy ICDs,[19](#jmri24971-bib-0019){ref-type="ref"} widespread adaptation of safety protocols has not occurred. In the course of evaluating a protocol for safely imaging ICD patients, a prospective study conducted 555 MRIs in 438 patients. They found devices of three patients reverted to back‐up programming mode and decreases in right ventricular (RV) sensing, as well as atrial, right and left ventricular lead impedances. Interrogations at 6 months showed decreased RV sensing, decreased RV lead impedance, increased RV capture threshold, and decreased battery voltage. It is important to note that none of the reported changes required device revision or reprogramming.[19](#jmri24971-bib-0019){ref-type="ref"} The MagnaSafe Registry reported on 500 patients with an ICD who have had a nonthoracic MRI. They report that no deaths, generator or lead failures, loss of capture, or ventricular arrhythmias occurred and found that one or more clinically relevant device parameter changes occurred in 29% of ICD patients. The generator of one ICD was later replaced due to inappropriate activation of tachytherapy during the MRI.[28](#jmri24971-bib-0028){ref-type="ref"} The hesitation to adopt such safety protocols is partially attributable to the current lack of an FDA‐approved MR‐conditional ICD and Medicare coverage restrictions regarding MRI scans in patients with ICDs. It is possible that with additional safety data the U.S. FDA and CMS will review and revise their MRI coverage policy; however, substantial safety data will understandably be needed.

An important outcome of our study is that more than half, 53%--64%, of ICD‐indicated patients are projected to require MRI within a decade, a result that is consistent with previous research.[4](#jmri24971-bib-0004){ref-type="ref"} Kalin and Stanton[4](#jmri24971-bib-0004){ref-type="ref"} reported that the combination of greater MRI use and more patients with ICDs coupled with expanded Medicare coverage leads to a projected range from 50% to 75% of ICD patients needing an MRI over the lifetime of the device.

This study adds to the literature, as it had sizeable cohorts to highlight the nominal use of MRIs in patients with ICDs, reflecting ongoing safety concerns.[13](#jmri24971-bib-0013){ref-type="ref"} Moreover, this research indicates the need for MR‐conditionally safe ICDs and appropriate protocols that will increase the likelihood that MRIs can be performed safely in individuals implanted with these devices. Currently, there is a growing body of research on careful use of MRIs in patients implanted with ICDs.[11](#jmri24971-bib-0011){ref-type="ref"}, [19](#jmri24971-bib-0019){ref-type="ref"}, [29](#jmri24971-bib-0029){ref-type="ref"} Van der Graaf et al[29](#jmri24971-bib-0029){ref-type="ref"} describe the status of MRI and implantable electronic devices, including ICDs, and report on four ongoing clinical trials studying MR‐conditional pacing devices. The European Society of Cardiology (ESC) on cardiac pacing and cardiac resynchronization therapy (CRT) recently published guidelines that suggest that MRI can be safely performed in patients with ICDs if strict safety conditions are met.[30](#jmri24971-bib-0030){ref-type="ref"} These guidelines represent a major shift in the previously accepted standard that patients with a pacemaker or ICD should not undergo MRI.[29](#jmri24971-bib-0029){ref-type="ref"}

There are several important limitations to consider. First, although data sources were large and contemporary, variables were based on medical claims designed for billing purposes, and unidentified confounders may be present, which could affect the precision of the prediction model. Second, we are unable to ascertain indication for imaging, which could help generate precise estimates of likelihood of need or MRI based on comorbidities, or clarify conditions or indications in which non‐MRI alternatives could be suitable. Third, findings may not be generalizable to other countries or non‐fee for service healthcare systems, which may have lower rates of imaging utilization. Finally, patient outcomes related to receiving MRI versus not could not be determined from this claims analysis.

In conclusion, MRI utilization is lower in ICD patients compared to nonimplant patients, and disparities are seen in access to MRI among the three subgroups of interest. One in 25 ICD patients would have qualified for imaging for a recorded stroke/TIA, yet less than 1% received MRI for this indication. We project that ∼53%--64% of ICD patients are likely to need an MRI over a 10‐year time horizon, highlighting the importance of MR‐conditional ICDs for this patient population.

Contract grant sponsor: Medtronic.
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CPT CodeExplant Type\# 00.50CRT‐P\# 00.50, 33208, 33225CRT‐P\# 00.50, 33225CRT‐P\# 00.50, 33207, 33225CRT‐P\# 37.72, 37.83, 33208, 33225CRT‐P\# 00.50, 33208CRT‐P\# 33208, 33225CRT‐P\# 00.50, 33207, 33208, 33225CRT‐P\# 33207, 33225CRT‐P\# 37.72, 37.83, 33225CRT‐P\# 37.83, 33208, 33225CRT‐P\# 37.72, 37.83Pacemaker\# 37.72, 37.83, 33208Pacemaker\# 37.72, 37.80, 33208Pacemaker\# 37.80,37.83, 33208Pacemaker\# 33208Pacemaker\# 37.72, 33208Pacemaker\# 37.72, 37.83, 33207, 33208PacemakerCode CombinationImplant Type\# 37.70, 37.83, 33208Pacemaker\# 37.72, 37.80, 37.83Pacemaker\# 37.72, 37.80, 37.83, 33208Pacemaker\# 37.72, 37.83, 33207, 33225Pacemaker\# 37.73, 37.80Pacemaker\# 37.73, 37.82, 33206, 33207Pacemaker\# 37.73, 37.82, 33208Pacemaker\# 37.80, 33206Pacemaker\# 37.80, 33207Pacemaker\# 37.82, 37.83, 33208Pacemaker\# 37.83, 33207Pacemaker\# 37.70, 37.82Pacemaker\# 33206Pacemaker\# 37.73, 37.81Pacemaker\# 3781,33206Pacemaker\# 37.73, 37.82Pacemaker\# 37.73, 37.82, 33206Pacemaker\# 37.73, 37.81, 33206Pacemaker\# 37.71, 37.81Pacemaker\# 37.71, 37.82PacemakerCode CombinationImplant Type\# 37.71, 37.82, 33207Pacemaker\# 37.71, 37.81, 33207Pacemaker\# 33207Pacemaker\# 37.81, 37.82, 33207Pacemaker\# 37.71, 37.81, 33207, 33208Pacemaker\# 37.71, 37.80Pacemaker\# 37.70, 37.81, 33207Pacemaker\# 00.51CRT‐D\# 00.51, 33225CRT‐D\# 00.51, 33249CRT‐D\# 00.51, 33249, 33225CRT‐D\# 33249, 33225CRT‐D\# 33249ICD\# 37.94ICD\# 37.94, 33249ICD\# 37.94, 37.95ICD\# 37.94, 37.95, 33249ICD\# 37.94, 37.95, 37.96, 33249ICD\# 37.94, 37.96, 33249ICD\# 37.95, 33249ICDCode CombinationImplant Type\# 37.95, 37.96ICD\# 37.96, 33249ICD\# 33282Reveal
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CPT CodeExplant Type\# 37.79ICD or CRT‐D\# 37.89PM\# 33227PM\# 33233PM\# 33234PM\# 33235PM\# 33236PM\# 33237PM\# 33238ICD or PM\# 33241ICD\# 33244ICD\# 33284ILR
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CPT CodeInterrogation Code Description\# 93279Pm Device Progr Eval Sngl\# 93280Pm Device Progr Eval Dual\# 93281Pm Device Progr Eval Multi\# 93282Icd Device Prog Eval 1 Sngl\# 93283Icd Device Progr Eval Dual\# 93284Icd Device Progr Eval Mult\# 93285Ilr Device Eval Progr\# 93288Pm Device Eval In Person\# 93289Icd Device Interrogate\# 93290Icm Device Eval\# 93291Ilr Device Interrogate\# 93293Pm Phone R‐Strip Device Eval\# 93294Pm Device Interrogate Remote\# 93295Icd Device Interrogat Remote\# 93296Pm/Icd Remote Tech Serv\# 93297Icm Device Interrogat Remote\# 93298Ilr Device Interrogat Remote\# 93299Icm/Ilr Remote Tech ServCPT CodeInterrogation Code Description\# 93287ICD Evaluation Peri‐procedural\# 93741ICD Evaluation (pre‐2009)\# 93742ICD Evaluation (pre‐2009)\# 93743ICD Evaluation (pre‐2009)\# 93744ICD Evaluation (pre‐2009)\# 93286PM Evaluation Peri‐procedural\# 93731PM Remote Evaluation (pre‐2009)\# 93732PM Remote Evaluation (pre‐2009)\# 93733PM Remote Evaluation (pre‐2009)\# 93734PM Remote Evaluation (pre‐2009)\# 93735PM Remote Evaluation (pre‐2009)\# 93736PM Remote Evaluation (pre‐2009)\# 93724PM Electronic Analysis\# 93641PM EP Evaluation\# 93642PM EP Evaluation
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ConditionICD9 CodeAngina411.1, 413.xAnkylosing Spondylitis720.0Atrial Fibrillation427.31Back Pain724.xx, 847.xxBronchiectasis494.xCardiac Dysrhythmias427.xxChronic Airway Obstruction NEC496Chronic Obstructive Asthma493.2xColon Cancer153.xCrohn\'s Disease555.xxCystitis595.xxDepressive Disorders311, 300.4, 309.0, 309.1, 309.28, 298.0, 296.2x, 296.3x, 296.5x, 296.6x, 296.8x (except 296.81)Diabetes249.xx, 250.xxDiverticulitis562.11, 562.13Eczema (Dermatitis)692.9Emphysema492.xExtrinsic Allergic Alveolitis495.xGastric Ulcer531.xxGastritis535.xx (except 535.6x)GERD530.81Heart Failure398.91, 402.x1, 404.x1, 404.x3, 428.xxHyperlipidemia272.0, 272.1, 272.2, 272.4, 272.9Hypertension401.x, 402.xx, 404.xx, 405.xxHypothyroidism243, 244.xHypertrophic Cardiomypathy425.11, 425.18Irritable Bowel Disease564.1Joint Pain716.xx, 718.xx 719.xxKidney Stones592.xLumbar Disk Disease722.10, 722.73, 722.52, 722.93Lung, Bronchus, or Trachea162.xMI (any)410.xx, 412, 411.0Migraine346.xxMultiple Sclerosis340Neurotic Disorders300.xx (without 300.4) + 309.81Obstructive Chronic Bronchitis491.2xOsteoarthritis721.x, 715.xxOsteoporosis733.0xOther Coronary Artery Disease411.81, 411.89, 414.0x, 414.2, 414.3, 414.4, 414.8, 414.9, 429.2, V45.81, V45.82Parkinson\'s disease332.xPsoriatic Arthritis696.0Rheumatoid Arthritis714.0Sarcoidosis135Sebaceous Gland Diseases706.xSkin Cancer176.0, 209.31--209.36, 172.x, 173.xSleep Apnea327.2x, 780.51, 780.53, 780.57Stroke430, 431, 432.x, 433.x1, 434.x1, 997.02TIA435.xUlcerative Colitis556.xxAnticoagulation (included any of these)Anisindione, Antithrombin III Human, Antithrombin, Recombinant, Apixaban, Ardeparin Sodium, Argatroban, Bivalirudin, Citric Acid/Dextrose/Na Cit/Na Phos, Citric Acid/Dextrose/Sodium Citrate, Dabigatran Etexilate Mesylate, Dalteparin Sodium, Danaparoid Sodium, Desirudin, Dextrose/Heparin Sodium, Dicumarol, Enoxaparin Sodium, Fondaparinux Sodium, Heparin, Heparin Calcium, Heparin Sodium, Heparin/Dihydroergotamine, Lepirudin, Phenprocoumon, Rivaroxaban, Sodium Citrate, Tinzaparin Sodium, Warfarin Potassium, Warfarin Sodium
